Diana Ntamu Nandagire
ID:
|
Small and Growing Businesses: A Segmentation Study in Uganda and Nigeria
REFNo: SS647ES
The purpose of the study is to test Dalberg’s segmentation framework of small and growing businesses (SGBs) by determining the effectiveness of that framework. By testing the framework, “maps†shall be created, funding gaps shall be established and recommendations made for the two African countries (Uganda and Nigeria).
The study will be guided by the following objectives;
a) To determine the extent to which the Dalberg framework defines SGBs in Uganda and Nigeria.
b) To establish the reasons why SGBs seek financing in their operations and the challenges in accessing funding.
c) To identify organisations that invest in SGBs and establish the proportion of their portfolio dedicated to SGBs.
d) To establish the total capital available in funding organisations to SGBs.
e) To establish the challenges of investing in SGBs.
|
Uganda |
2020-12-18 |
2023-12-18 |
Social Science and Humanities |
|
Non-degree Award |
|
Florence Nassiwa
ID:
|
Effect of climate variability adaptation strategies on livelihood of smallholder vegetable farmers in Kampala District Uganda
REFNo: SS649ES
i. To establish the effect of technological development adaptation strategies on livelihood of smallholder vegetable farmers.
ii. To determine the effect of government programs and insurance adaptation strategies on livelihood of smallholder vegetable farmers.
iii. To assess the effect of farm production adaptation strategies on livelihood of smallholder vegetable farmers
iv. To establish the effect of farm financial management adaptation strategies on livelihood of smallholder vegetable farmers.
v. To evaluate constraints smallholder vegetable farmers encounter in adapting to climate variability.
|
Uganda |
2020-12-18 |
2023-12-18 |
Social Science and Humanities |
|
Degree Award |
|
Kamya Moses
ID: UNCST-2020-R014203
|
Impact of housing modifications combined with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) on the malaria burden in Uganda: a cluster-randomised trial
REFNo: HS1072ES
Primary Objective;
To evaluate the effect of housing modifications plus PBO LLINs, compared to PBO LLINs alone, on the incidence of clinical malaria in Ugandan children aged < 60 months
Secondary Objectives;
1) Epidemiology: To assess the impact of housing modifications + PBO LLINs, compared to PBO LLINs alone, on (1) parasite prevalence, and (2) prevalence of anaemia in children 6m-14y
2) Entomology: To assess the impact of housing modifications + PBO LLINs, compared to PBO LLINs alone, on (1) indoor and outdoor densities of malaria vectors; (2) entomological inoculation rate (EIR); (3) human biting rates (indoor and outdoor); and (4) To evaluate the patterns of insecticide resistance through the phenotypic and molecular detection methods, in mosquito vectors from clusters with housing modification + PBO LLINs, compared to PBO LLINs alone
3) Housing modifications: (1) To understand the local context regarding housing; (2) To assess acceptability of the housing modification interventions quantitatively, among the cohort members and the community, over time; (3) To assess acceptability of the housing modification interventions through qualitative research among the community opinion leaders and members, in both intervention and control clusters, over time; (4) To assess durability of housing modification interventions; (5) To assess environmental measures in houses with modifications + PBO LLINs; (6) To assess feasibility of housing modification including labour and materials, maintenance requirements, time required; (7) To conduct a process evaluation of the interventions, by developing a logic model, assessing the implementation of the housing modifications, and examining the mechanisms of effect
4) Economics: (1) To measure cost-effectiveness of housing modifications + PBO LLINs, compared to PBO LLINs alone, under research conditions; (2) To cost the different components of the interventions and identify factors contributing to major costs; (3) To estimate potential cost of providing housing interventions at scale over longer periods of time.
|
Uganda |
2020-12-18 |
2023-12-18 |
Medical and Health Sciences |
|
Non-degree Award |
|
Elly Katabira
ID:
|
REDUCING STROKE BURDEN IN UGANDA USING TARGETED MANAGEMENT INTERVENTION (TEAM). A RANDOMISED, PROSPECTIVE 6 – MONTH CONTROLLED TRIAL.
REFNo: HS1094ES
Objective 1: To refine the TEAM curriculum for optimal acceptability and integration in the Ugandan setting guided by input from stakeholders (patients/family, clinicians, administrators).
Objective 2: To conduct an RCT comparing efficacy of TEAM vs. enhanced treatment as usual (ETAU) in 246 Ugandans (TEAM, N= 123; ETAU, N= 123) at high risk for stroke.
Objective 3: Identify barriers and facilitators to TEAM implementation.
|
Uganda |
2020-12-18 |
2023-12-18 |
Medical and Health Sciences |
|
Non-degree Award |
|
Joseph Lutaakome
ID: UNCST-2020-R008323
|
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19
REFNo: HS1099ES
SARS-CoV-2 is a novel coronavirus causing COVID-19 and has spread very rapidly. Safe and effective treatments are urgently needed. One antiviral treatment, remdesivir, and an anti-inflammatory drug, dexamethasone, have shown benefit; these are now the COVID-19 standard-of-care treatment for in patients in many parts of the world. The structure of the natural antibodies that hasten recovery from COVID-19 are now known; this means synthetic forms have been manufactured. These synthetic neutralising monoclonal antibodies (nMAb) ‘neutralise’ the virus by binding to it and prevent it from entering cells in the body, including the lungs. By giving an infusion of these nMAb(s) in addition to COVID-19 standard-of-care treatment, we hope hospitalised patients will recover more quickly.
The primary endpoint of TICO is to test whether in hospitalized adults with confirmed COVID-19 infection, the nMAb(s) result in more people with ‘sustained’ recovery i.e. discharged from hospital, alive, and home for 14 consecutive days by Day 90.
1) For everyone enrolled during stage 1 and 2 of the trial the secondary research questions are to define, the numbers of deaths through 90 days of follow-up; the number of people who experience sustained recovery over 90 days, the time to discharge from the initial hospital, and the number of days alive up to day 90.
2) Changes in the scores to assess people’s lung and respiratory function on Days 1-7, and Days 14 and 28.
3) Changes between Day 0 and Day 5 in the National Early Warning (NEW) score, this is a scoring system validated in the UK, which is able to score how sick people are, and their risk of dying, based on things like their blood pressure, pulse rate and body temperature.
4) Clinical organ failure defined by development of any one or more of the following through Day 28
a. Respiratory system dysfunction including the need for oxygen therapy or ventilation
b. Cardiac problems include heart attacks and heart failure
c. Low blood pressure requiring drug support to maintain it
d. kidney dysfunction including needing dialysis
e. liver dysfunction including liver failure and abnormal liver tests
f. Brain and nerve problems including acute confusion, strokes, brain swelling, meningitis, and weakness of the legs
g. Blood problems including major bleeding
h. thrombotic events in the veins or arteries
i. Serious infections including sepsis.
5) Safety and tolerability as measured by: grade 3 and 4 clinical adverse events, serious adverse events, or death through Day 5 and through Day 28; Infusion-related reactions of any severity and the percentage of participants for whom the infusion was interrupted or stopped prior to completion.
6) Change in the levels and types of antibodies against COVID-19, from baseline to Days 1, 3, 5 and 28 and 90.
|
Uganda |
2020-12-18 |
2023-12-18 |
Medical and Health Sciences |
|
Non-degree Award |
|
Patrick Wakida
ID:
|
MARKET RESEARCH STUDY TO UNDERSTAND THE MARKET POTENTIAL FOR CANCER TESTING EQUIPMENT IN UGANDA
REFNo: SS679ES
i. To understand current diagnostic and treatment pathways in breast cancer.
ii. To gain an understanding of breast cancer management including mapping diagnostic and treatment pathways
iii. To understand the processes and challenges of penetrating the invitro diagnostics products market the Uganda.
iv. To determine the need for molecular invitro diagnostics product In Uganda
|
Uganda |
2020-12-18 |
2023-12-18 |
Social Science and Humanities |
|
Non-degree Award |
|
Nelson Sewankambo K
ID: UNCST-2020-R014578
|
Feasibility and acceptability of Dialog+ in Primary care-Uganda
REFNo: HS1116ES
i. test the feasibility and acceptability of DIALOG+ for patients with non-communicable physical health conditions in primary care
ii. explore the adaption of Dialog+ intervention through a process of stakeholder consultation and refine the training materials to promote wider implementation and upscale
iii. explore the effect of using the adapted Dialog+ intervention on patient outcomes
|
Uganda |
2020-12-18 |
2023-12-18 |
Medical and Health Sciences |
|
Non-degree Award |
|
Catherine Mwesigwa
ID: UNCST-2019-R000988
|
FEASIBILITY OF INTEGRATING ORAL HEALTH IN THE PRIMARY CARE OF HIV PEDIATRIC PATIENTS IN KAMPALA, UGANDA
REFNo: HS1055ES
1. To determine the factors that influence integrating oral health at pediatric HIV care facilities.
2. To assess the effectiveness of an oral health education intervention in pediatric HIV care.
3. To explore the feasibility of integrating oral health within primary HIV-care in a low-resource setting
|
Uganda |
2020-12-17 |
2023-12-17 |
Medical and Health Sciences |
|
Non-degree Award |
|
Nazarius Tumwesigye Mbona
ID: UNCST-2019-R000664
|
Research Protocol for the Impact and Economic Evaluation of Health Systems Strengthening Interventions in the West Nile region of Uganda
REFNo: HS1110ES
To determine the status and associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of coverage of maternal and child health and nutrition services in intervention and counterfactual districts during 2019
2: To determine the status and associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of use of maternal and child health and nutrition services in intervention and counterfactual districts during 2019
3: To determine the differences and the associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of the change in coverage of maternal and child health and nutrition services from 2019 to 2024 between intervention and counterfactual districts
4: To determine the differences and the associated factors (i. DHSS intervention, ii. Quality of Care, iii. SBCC) of the change in use of maternal and child health and nutrition services from 2019 to 2024 between intervention and counterfactual districts
5: To establish the cost and effectiveness of DHSS, quality improvement and SBCC in the use and coverage of maternal and child health and nutrition services from 2019-2024
|
Uganda |
2020-12-17 |
2023-12-17 |
Medical and Health Sciences |
|
Non-degree Award |
|
Grace Kaisa Tibagwa
ID:
|
Analysing routine patient data collected through the LifeHealth Network for trends of clinical and public health importance
REFNo: HS1007ES
To analyse data of patients with infectious diseases (such as malaria, HIV, TB), non-communicable diseases (such as cancer, diabetes) and serious health conditions (such as sickle cell anaemia) subscribing to the LifeHealth model for any trends of clinical and public health importance.
|
Uganda |
2020-12-16 |
2023-12-16 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|